In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. One hundred patients (receiving 123 conditioning regimens) were included in the analysis. Criteria for discharge were presence of myeloid engraftment and absence of severe concomitant problems. Ninety subjects (73%) were discharged just after engraftment was reached on day +12 (10-14). Discharge was delayed in 33 patients (27%) and the mean prolongation was 3 days (1-11). In 31 patients (25%) delayed discharge was due to complications: in 14 patients (11.4%) because of GIT problems, in 16 patients (13%) because of infectious complications and in one patient because of cardiotoxicity. A significantly higher number of infectious complications was found in patients conditioned with BEAM (19.7% vs 4.2%, P Ͻ 0.05) while GIT toxicity was the most common reason for discharge delays in patients conditioned with melfalan 200 mg/m 2 (8.2% vs 14.7%, NS). No risk factors of hospital stay prolongation were determined. We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. Bone Marrow Transplantation (2000) 26, 877-880.
High-dose chemotherapy (HDC) followed by autologous blood stem cell transplantation (BSCT) is used to treat many hematological malignancies. [1] [2] [3] However, these innovative therapeutic modalities are very expensive. To reduce overall costs, transplant centers have used such strategies as relocation of many aspects of transplant care to out-patient departments or the home setting, reducing phar- macy costs and introduction of peripheral BSCT (PBSCT). [4] [5] [6] [7] [8] [9] [10] [11] Rationale for performing PBCST is that several studies have found more rapid hematopoietic reconstitution after PBSCT (compared with bone marrow). 1, [4] [5] [6] [7] [8] [9] [10] [11] [12] Based on these studies, this treatment modality has raised hopes that it will result not only in more rapid engraftment, but also in reduced in-patient stay and thus in reduction of overall costs. However, despite these innovations, several important problems which cannot be easily overcome remain. Due to delayed recovery from severe HDC-related non-hematological (especially gut) toxicities and due to persistent infections, the in-patient stay in some cases must be prolonged beyond the point of engraftment. 13 Thus, initial hopes have been only partly fulfilled in the majority of patients that faster hematopoietic reconstitution after PBSCT really has led to a shortened hospital stay.
In order to assess the incidence and analyze reasons for delay in discharge from hospital in engrafted patients, we reviewed 100 patients, receiving 123 conditioning regimens for non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), multiple myeloma (MM) or breast cancer.
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Patients and methods
Patients
Between November 1996 and February 1999, 100 patients (receiving 123 conditioning regimens as 23 patients received tandem HDC and PBSCT) with NHL, HD, MM and breast cancer were included in a retrospective analysis (characteristics are shown in Table 1 ). The mean number of transplanted CD34
+ cells: 6.3 × 10 6 /kg (3.0-14.3). Double HDC was applied in two NHL patients, 10 MM patients and 11 women with breast cancer. 
Transplant protocols and G-CSF use
The pre-transplant conditioning regimen (BEAM) for NHL (two patients received two cycles of BEAM) and HD patients consisted of BCNU (300 mg/m All patients received G-CSF, 10 g/kg/day from day +4 (+2-+7), the first day the ANC dropped below 0.5 × 10 9 /l. 4 
Criteria for discharge
Patients were discharged when they were afebrile with evidence of myeloid engraftment (the ANC exceeded 0.5 × 10 9 /l), with an unsupported platelet count of more than 10 × 10 9 /l (without signs of bleeding) and when no other severe concomitant problems, especially infections or signs of important, organ-specific non-hematological toxicity, were present.
Supportive care
Patients were hospitalized in single rooms with (HEPA) or without air filtration. An indwelling central venous catheter was inserted in all cases. All patients received a standard prophylactic antibiotic, antifungal and antiviral regimen (quinolone, fluconazole or itraconazole and acyclovir). Patients developing fever over 38°C during the neutropenic period were treated with an empiric combination of broad spectrum antibiotics according to the institutional protocol. Irradiated packed red blood cells were transfused as required to maintain the hemoglobin level over 80 g/l, prophylactic irradiated single donor platelet transfusions were given to maintain the platelet count over 10 × 10 9 /l.
Mobilization of PBSC
PBSCs in the majority of patients were collected as previously described. 15 Briefly, patients had peripheral blood stem and progenitor cells mobilized with cyclophosphamide (CY) 3 g/m 2 and G-CSF 5 g/kg/day subcutaneuosly, started 24 h after CY and continued until the last day of leukapheresis. Apheresis of 20 liters blood using the Fenwall CS 3000+ (Baxter, Deerfield, IL, USA) or Cobe Spectra (Cobe, Lakewood, CO, USA) was performed. Leukapheresis began as the total WBC increased through 1.0 × 10 9 /l and more than 10 CD34
+ cells/l were detected. Leukapheresis was performed daily until more than 3 × 10 6 /kg CD34 + cells had been collected. Harvested cells were cryopreserved in 10% dimethyl sulfoxide and stored in the liquid phase of liquid nitrogen. On the day of PBSCT, they were thawed rapidly at the bedside and reinfused. 
Statistical analysis
Analyses were performed using a statistical software system (BMDP, Statistical Software, Los Angeles, CA, USA).
Comparison between quantitative variables was performed using the Mann-Whitney U test and between qualitative variables using 2 . In addition, times to ANC greater than 0.5 × 10 9 /l and 1.0 × 10 9 /l, and to platelets greater than 20 × 10 9 /l, as well as length of in-patient stay were analyzed with the log-rank test. A P value less than 0.05 was considered statistically significant. Results were expressed as median and range.
Results
Ninety post-transplant courses (73%) were accompanied by no or only short-duration complications with patients being discharged on time, just after engraftment had occurred on day +12 (+10-+14) following transplantation ( Table 2) .
Thirty-three post-transplant courses (27%) were associated with delayed discharge. Prolongation of hospital stay due to HDC-related complications were found in 25% of post-transplant courses (n = 31), the mean prolongation was 3 days (1-11). Fourteen patients (11.4%) stayed 3 days (1-11) longer in hospital because of gastro-intestinal (GIT) problems including nausea, vomiting and abdominal pain. Length of in-patient stay in 13% post-transplant courses (n = 16) was prolonged for 3 days (2-6) due to infectious complications including 11 cases of fever of undetermined origin (FUO), three cases of staphylococcal bacteremia and two of pneumonitis.
When the patients were subdivided into groups according to conditioning regimen, results were different (the differences between the patients conditioned with HD-L-PAM and those receiving BEAM are expressed in Table 3 ). A significantly higher number of infectious complications was found in patients conditioned with BEAM (12/61 BEAM No other risk factors for hospital stay prolongation were determined (Table 4) . Age-related complications were equally distributed among patients sorted according to decade. Diagnosis, sex, number and type of previous chemotherapeutic cycles, second PBSCT, transplanted dose of CD34 + cells were also not relevant. We also observed no significant difference in discharge delay between patients receiving the first or the second HDC ( Table 4) .
The discharge delay (2 days) in one female patient with MM was due to paroxysmal atrial fibrillation which was probably a consequence of cardiotoxicity of HD-L-PAM.
Two patients stayed longer in hospital (3 days) because of collection of PBSC during the recovery phase after aplasia.
An ANC of more than 0.5 × 10 9 /l and 1 × 10 9 /l was reached on day +9 (8-12) and +10 (8-13), respectively. An unsupported platelet count of more than 20 × 10 9 /l was reached on day +12 (8-17). Table 4 Influence of patient characteristics and chemotherapy regimen on discharge delays ; CECb = cyclophosphamide, etoposide, carboplatin; GIT = gastro-intestinal tract; NS = not significant.
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Discussion
Several studies have shown that PBSCT is more cost-effective than bone marrow transplantation. Transplantation of an optimal number of autologous PBSC (more than 5.0 × 10 6 CD34 + cells per kg) results in prompt and durable trilineage hematopoietic recovery after HDC, with neutrophil recovery usually occurring 9 to 10 days and platelet recovery 10 to 12 days following transplant. 1, 2, 11, 12 The hope has been that the faster recovery in the neutrophil count may lead to shortened hospital stay due to quicker resolution of overall toxicity. However, the ultimate benefit of faster hematological recovery may be lost as non-hematological toxicities and infections may persist in some patients beyond the point of engraftment resulting in a longer hospital stay.
Our results show that in spite of rapid engraftment, nonhematological toxicities and infectious complications remain the determinants of duration of hospitalization in a significant portion (nearly one quarter) of patients after PBSCT. Thus, one would expect that a similar number of patients may require hospital admission if they are transplanted in the out-patient or home settings. Fourteen patients were delayed because of GIT-related complications, and a similar number of patients (n = 16) because of infectious complications. It is interesting to note that significantly more infectious complications were diagnosed in NHL patients conditioned with BEAM and that GIT toxicity was the most common reason for discharge delays in patients conditioned with HD-L-PAM. On multivariate analysis we were not able to identify any statistically significant risk factor for hospital stay prolongation. Transplant-related non-hematological toxicity was surprisingly not excessive in our elderly patients although one would perhaps expect a higher incidence due to more compromised organ function in this older population. 16 In our study the findings that multiple cycles of standard-dose chemotherapy may be connected with worse outcome of HDC, 12, 17 were not confirmed. The clinical outcome of patients receiving more or less intensive first-line therapy was similar. Surprisingly, the less intensive regimen (HD-L-PAM) did not result in a quicker patient discharge than the more intensive pre-transplant conditioning CECb.
Acute cardiotoxicity is a rare complication of HDC and PBSCT. 18 In our study this reversible toxicity (atrial fibrillation) occurred in only one female patient, and arose in the absence of any predisposing factors or history of coronary or other heart disease.
